Digital Pathology Market

The Digital Pathology Market is valued at USD 1.6 Bn in 2026 and is projected to reach USD 3 Bn, growing at a CAGR of 9% by 2033.

Inclination Toward Enhancing Lab Efficiency Remains Instrumental to Digital Pathology Market Growth

Increasing focus on improving lab efficiency has resulted in adoption of new techniques. This has influenced use of digital pathology system that enhances efficacy of laboratories alongside significantly reducing lab costs. In addition, digital pathology also facilitates reduction in turnaround times and enabling users to gain access to critical data and detailing. Moreover, enhancement of laboratory efficiency is crucial as physicians are dependent on laboratory results for diagnosis of patients based on which critical decisions are made. With higher efficiency of laboratory, diagnostic tests could be carried out effectively and the diagnosis results can be reported on time, which becomes a pivotal aspect in patient success. Moreover, access to slides via digital platform and web services can eliminate costs associated with shipping along with the travel time needed for pathologists. Digital pathology plays a vital role in enhancing laboratory workflow and carrying crucial functions such as capturing of data, its storage and image sharing with telehealth and healthcare providers. This factor remains crucial in driving the growth of the digital pathology market on the global front. In addition, with pervasive technological advancements, the medical diagnosis space is witnessing a new horizon with the inclusion of digital pathology solutions and systems. With virtual screening of tests provided by pathologists, physicians can conveniently provide teleconsultation, education, training, and diagnosis and possible effects of the disease.

Healthcare IT Solutions to Pave an Opportunistic Landscape

Widespread adoption of technology has transformed various industrial sectors, and this continues to further improve at a significant rate. Healthcare industry being no exception to the technological paradigm, penetration of new age tech such as artificial intelligence and machine learning has renovated several processes including the pathology domain. In a bid to ensure high quality patient care, adoption of Artificial Intelligence has prevailed in pathological diagnosis. Different AI based systems such as CDSS (Clinical Support Decision Systems) enable streamlining of process workflow in healthcare facilities such as hospitals and pathology centres, consequently enhancing medical care.

In this background, healthcare organisations are partnering with technology companies to improve their digital experience to improve patient outcome. For instance, in 2021, Roche announced its partnership with PathAI, a company providing advanced technology solutions such as deep learning, machine learning, and AI with an aim to improve pathology. Under this agreement, an embedded image workflow analysis would be developed for pathologists. This collaboration is expected to bring several components essential to deliver AI based pathology device comprising of assays, scanners, algorithms, and image management systems. That said, rising penetration of novel healthcare IT solutions is expected to bolster growth of the digital pathology market.

Digital Pathology Devices to Account for a Significant Share in the Market

The adoption of advanced digital pathology devices has been witnessed since the recent past. Increasing use of devices such as slide management systems and scanners are expected to largely contribute towards value growth of the digital pathology market. This can be attributed towards growing number of academic research initiatives coupled with increasing demand for enhanced resolution. Moreover, with advances in scanning and magnification offered by techniques such as whole slide imaging, the demand for digital pathology devices is expected to further grow. In this backdrop, companies are focusing on developing advanced and high-quality devices in the pathology space. For instance, in 2021, OptraSCAN developed the OS-Ultra 320 high speed scanners. This device is capable of scanning cells and tissues of size of about 15x15 mm area at a magnification of 40x within a minute. Furthermore, benefits of digital pathology devices such as enhanced productivity, better patient outcome, and reduced costs have fuelled their sales. That said, scanning and other devices are likely to account for a prominent revenue share in the digital pathology market.

North America Likely to Hold a Prominent Share

Developed economies across North America continue to reflect high market attractiveness for digital pathology. This is mainly owing to better healthcare infrastructure, stable rise in GDP and economic growth and favourable government initiatives promoting use of technologically advanced healthcare systems. This aspect has also resulted in major companies in the digital pathology space to set foot hold in the region. This factor remains instrumental in fuelling growth of the digital pathology market in North America, making it an opportunistic go-to-region.

Digital Pathology Market: Competitive Landscape

Few of the major players in the digital pathology market include:

• Leica Biosystems
• Roche Diagnostics
• Philips Healthcare
• GE HealthCare
• Siemens Healthineers
• Olympus Corporation
• Hamamatsu Photonics K.K.
• 3DHISTECH Ltd.
• Visiopharm A/S
• Indica Labs, Inc.
• Inspirata, Inc.
• Paige AI, Inc.
• Sectra AB
• Koninklijke Philips N.V.
• Fujifilm Holdings Corporation

The Global Digital Pathology Market is Segmented as Below:

By Product

• Devices (Scanners and Slide Management System)
• Software

By Application

• Drug Discovery & Development
• Academic Research
• Disease Diagnosis

By End User

• Hospitals
• Biotech & Pharma Companies
• Diagnostic Labs
• Academic & Research Institutes

By Region

• North America
• Europe
• Asia Pacific
• LAMEA